Axicabtagene Ciloleucel for Follicular Lymphoma
(ZUMA-22 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is Axicabtagene Ciloleucel (Yescarta) safe for humans?
Axicabtagene ciloleucel (Yescarta) has been used in various studies for different types of lymphoma, showing a manageable safety profile. Common side effects include cytokine release syndrome (a reaction that can cause fever and low blood pressure), neurological issues, infections, fever, diarrhea, nausea, low blood pressure, and fatigue.12345
How is the treatment axicabtagene ciloleucel unique for follicular lymphoma?
What data supports the effectiveness of the treatment Axicabtagene Ciloleucel for Follicular Lymphoma?
Research shows that Axicabtagene Ciloleucel (axi-cel) is effective for patients with relapsed or refractory follicular lymphoma, with high response rates and durable remissions observed in the ZUMA-5 study. It is considered a promising option for patients who have not responded to other treatments.12468
Who Is on the Research Team?
Kite Study Director
Principal Investigator
Kite, A Gilead Company
Are You a Good Fit for This Trial?
This trial is for adults with a confirmed diagnosis of follicular lymphoma who need treatment and have at least one measurable lesion. They must have had the disease return or not respond after initial therapy, including those whose disease came back within 24 months or after two treatments. Pregnant women, individuals with certain nervous system disorders, severe neuropathy, active infections (including HIV and hepatitis), autoimmune diseases, cardiac issues in the past six months, prior CD19-targeted therapies or CAR T-cell therapies cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either axicabtagene ciloleucel or standard of care therapy, including Rituximab-based regimens
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term Follow-up
Participants who received axicabtagene ciloleucel transition to a separate study for continued monitoring
What Are the Treatments Tested in This Trial?
Interventions
- Axicabtagene Ciloleucel
Axicabtagene Ciloleucel is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kite, A Gilead Company
Lead Sponsor